A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells

被引：62

作者：

de Bruin, Renee C. G. ^{[1
]}

Veluchamy, John P. ^{[1
]}

Lougheed, Sinead M. ^{[1
]}

Schneiders, Famke L. ^{[1
]}

Lopez-Lastra, Silvia ^{[2
,3
,4
]}

Lameris, Roeland ^{[1
]}

Stam, Anita G. ^{[1
]}

Sebestyen, Zsolt ^{[5
,6
]}

Kuball, Juergen ^{[5
,6
]}

Molthoff, Carla F. M. ^{[8
]}

Hooijberg, Erik ^{[7
]}

Roovers, Rob C. ^{[9
]}

Di Santo, James P. ^{[2
,3
]}

Henegouwen, Paul M. P. van Bergen En ^{[9
]}

Verheul, Henk M. W. ^{[1
]}

de Gruijl, Tanja D. ^{[1
]}

van der Vliet, Hans J. ^{[1
]}

机构：

[1] Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, Room 3A38,De Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands

[2] Inst Pasteur, Innate Immun Unit, Paris, France

[3] INSERM, U1223, Paris, France

[4] Univ Paris Sud, Univ Paris Saclay, Gif Sur Yvette, France

[5] Univ Med Ctr Utrecht, Dept Hematol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands

[6] Univ Med Ctr Utrecht, Lab Translat Immunol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands

[7] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, De Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands

[8] Vrije Univ Amsterdam, Med Ctr, Dept Radiol & Nucl Med, De Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands

[9] Univ Utrecht, Fac Sci, Dept Cell Biol, Padualaan 8, NL-3584 Utrecht, Netherlands

来源：

ONCOIMMUNOLOGY | 2018年 / 7卷 / 01期

关键词：

cancer; EGFR; gamma delta T cells; immunotherapy; nanobody; single-domain antibody fragment; tumor; VHH; DELTA T-CELLS; METASTATIC COLORECTAL-CANCER; ANTIBODY FRAGMENTS; SOLID TUMORS; PROGNOSTIC-SIGNIFICANCE; EGF RECEPTOR; IMMUNOTHERAPY; RECOGNITION; GROWTH; PHOSPHOANTIGENS;

D O I：

10.1080/2162402X.2017.1375641

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Though V gamma 9V delta 2-T cells constitute only a small fraction of the total T cell population in human peripheral blood, they play a vital role in tumor defense and are therefore of major interest to explore for cancer immunotherapy. V gamma 9V delta 2-T cell-based cancer immunotherapeutic approaches developed so far have been generally well tolerated and were able to induce significant clinical responses. However, overall results were inconsistent, possibly due to the fact that these strategies induced systemic activation of V gamma 9V delta 2-T cells without preferential accumulation and targeted activation in the tumor. Here we show that a novel bispecific nanobody-based construct targeting both V gamma 9V delta 2-T cells and EGFR induced potent V gamma 9V delta 2-T cell activation and subsequent tumor cell lysis both in vitro and in an in vivo mouse xenograft model. Tumor cell lysis was independent of KRAS and BRAF tumor mutation status and common V gamma 9V delta 2-T cell receptor sequence variations. In combination with the conserved monomorphic nature of the V gamma 9V delta 2-TCR and the facile replacement of the tumor-specific nanobody, this immunotherapeutic approach can be applied to a large group of cancer patients.

引用

页数：14